{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:41:06Z","timestamp":1792874466923,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The PI3K\/Akt\/mTOR signalling network is activated in almost 90% of all glioblastoma, the most common primary brain tumour, which is almost invariably lethal within 15 months of diagnosis. Despite intensive research, modulation of this signalling cascade has so far yielded little therapeutic benefit, suggesting that the role of the PI3K network as a pro-survival factor in glioblastoma and therefore a potential target in combination therapy should be re-evaluated. Therefore, we used two distinct pharmacological inhibitors that block signalling at different points of the cascade, namely, GDC-0941 (Pictilisib), a direct inhibitor of the near apical PI3K, and Rapamycin which blocks the side arm of the network that is regulated by mTOR complex 1. While both substances, at concentrations where they inhibit their primary target, have similar effects on proliferation and sensitisation for temozolomide-induced apoptosis, GDC-0941 appears to have a stronger effect on cellular motility than Rapamycin. In vivo GDC-0941 effectively retards growth of orthotopic transplanted human tumours in murine brains and significantly prolongs mouse survival. However, when looking at genetically identical cell populations that are in alternative states of differentiation, i.e. stem cell-like cells and their differentiated progeny, a more complex picture regarding the PI3K\/Akt\/mTOR pathway emerges. The pathway is differently regulated in the alternative cell populations and, while it contributes to the increased chemo-resistance of stem cell-like cells compared to differentiated cells, it only contributes to the motility of the latter. Our findings are the first to suggest that within a glioblastoma tumour the PI3K network can have distinct, cell-specific functions. These have to be carefully considered when incorporating inhibition of PI3K-mediated signals into complex combination therapies.<\/jats:p>","DOI":"10.1038\/s41389-017-0004-8","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T14:34:23Z","timestamp":1511534063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["The effects of PI3K-mediated signalling on glioblastoma cell behaviour"],"prefix":"10.1038","volume":"6","author":[{"given":"Julia","family":"Langhans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Schneele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Trenkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"von Bandemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nonnenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Karpel-Massler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus D.","family":"Siegelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Eric","family":"Halatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike-Andrew","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","volume":"375","author":"IF Tannock","year":"2016","unstructured":"Tannock, I. F. & Hickman, J. A. Limits to personalized cancer medicine. N. Engl. J. Med. 375, 1289\u20131294 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"4_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","volume":"45","author":"EC Lien","year":"2017","unstructured":"Lien, E. C., Dibble, C. C. & Toker, A. PI3K signaling in cancer: beyond AKT. Curr. Opin. Cell. Biol. 45, 62\u201371 (2017).","journal-title":"Curr. Opin. Cell. Biol."},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","volume":"7","author":"W Zhao","year":"2017","unstructured":"Zhao, W., Qiu, Y. & Kong, D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm. Sin. B 7, 27\u201337 (2017).","journal-title":"Acta Pharm. Sin. B"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","volume":"7","author":"X Li","year":"2016","unstructured":"Li, X. et al. PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7, 33440\u201333450 (2016).","journal-title":"Oncotarget"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","volume":"319","author":"YY Zaytseva","year":"2012","unstructured":"Zaytseva, Y. Y., Valentino, J. D., Gulhati, P. & Mark Evers, B. mTOR inhibitors in cancer therapy. Cancer Lett. 319, 1\u20137 (2012).","journal-title":"Cancer Lett."},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Network TCGAR.","year":"2008","unstructured":"Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","journal-title":"Nature"},{"key":"4_CR10","first-page":"279","volume":"347","author":"QW Fan","year":"2010","unstructured":"Fan, Q. W. & Weiss, W. A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr. Top Microbiol. Immunol. 347, 279\u2013296 (2010).","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2005.05881.x","volume":"132","author":"GV Georgakis","year":"2006","unstructured":"Georgakis, G. V. et al. Inhibition of the phosphatidylinositol-3 kinase\/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br. J. Haematol. 132, 503\u2013511 (2006).","journal-title":"Br. J. Haematol."},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97\u2013109 (2007).","journal-title":"Acta Neuropathol."},{"key":"4_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007752","volume":"4","author":"C Brennan","year":"2009","unstructured":"Brennan, C. et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4, e7752 (2009).","journal-title":"PLoS ONE"},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","volume":"107","author":"DR Johnson","year":"2011","unstructured":"Johnson, D. R. & O'Neill, B. P. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 107, 359\u2013364 (2011).","journal-title":"J. Neurooncol."},{"key":"4_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131670","volume":"10","author":"S Str\u00f6bele","year":"2015","unstructured":"Str\u00f6bele, S. et al. A potential role for the inhibition of PI3K signaling in glioblastoma therapy. PLoS ONE 10, e0131670 (2015).","journal-title":"PLoS ONE"},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"JT Huse","year":"2010","unstructured":"Huse, J. T. & Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319\u2013331 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"4_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/2052-8426-2-32","volume":"2","author":"MA Westhoff","year":"2014","unstructured":"Westhoff, M.-A. et al. A critical evaluation of PI3K inhibition in glioblastoma and neuroblastoma therapy. Mol. Cell. Ther. 2, 32 (2014).","journal-title":"Mol. Cell. Ther."},{"key":"4_CR18","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1002\/ijc.29138","volume":"136","author":"L Nonnenmacher","year":"2015","unstructured":"Nonnenmacher, L. et al. RIST: A potent new combination therapy for glioblastoma. Int. J. Cancer 136, E173\u2013E187 (2015).","journal-title":"Int. J. Cancer"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1021\/jm800295d","volume":"51","author":"AJ Folkes","year":"2008","unstructured":"Folkes, A. J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522\u20135532 (2008).","journal-title":"J. Med. Chem."},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li, J., Kim Sang, G. & Blenis, J. Rapamycin: one drug, many effects. Cell. Metab. 19, 373\u2013379 (2014).","journal-title":"Cell. Metab."},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.1158\/0008-5472.CAN-07-6769","volume":"68","author":"D Opel","year":"2008","unstructured":"Opel, D. et al. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res. 68, 6271\u20136280 (2008).","journal-title":"Cancer Res."},{"key":"4_CR22","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1038\/onc.2009.215","volume":"28","author":"MA Westhoff","year":"2009","unstructured":"Westhoff, M. A. et al. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 28, 3586\u20133596 (2009).","journal-title":"Oncogene"},{"key":"4_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083128","volume":"8","author":"MA Westhoff","year":"2013","unstructured":"Westhoff, M. A. et al. Sequential dosing in chemosensitization: targeting the PI3K\/Akt\/mTOR pathway in neuroblastoma. PLoS ONE 8, e83128 (2013a).","journal-title":"PLoS ONE"},{"key":"4_CR24","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1158\/1078-0432.CCR-04-2115","volume":"11","author":"TW Vogel","year":"2005","unstructured":"Vogel, T. W. et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin. Cancer Res. 11, 3624\u20133632 (2005).","journal-title":"Clin. Cancer Res."},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1541-7786.MCR-07-0280","volume":"6","author":"A Li","year":"2008","unstructured":"Li, A. et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 6, 21\u201330 (2008).","journal-title":"Mol. Cancer Res."},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/ijc.29908","volume":"138","author":"M Schneider","year":"2016","unstructured":"Schneider, M. et al. A paired comparison between glioblastoma \"stem cells\" and differentiated cells. Int. J. Cancer. 138, 1709\u20131718 (2016).","journal-title":"Int. J. Cancer."},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/sj.onc.1210850","volume":"27","author":"PC De Witt Hamer","year":"2008","unstructured":"De Witt Hamer, P. C. et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27, 2091\u20132096 (2008).","journal-title":"Oncogene"},{"key":"4_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/sj.cdd.4401359","volume":"11","author":"T Kanzawa","year":"2004","unstructured":"Kanzawa, T. et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11, 448\u2013457 (2004).","journal-title":"Cell Death Differ."},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.freeradbiomed.2011.10.487","volume":"52","author":"CJ Lin","year":"2012","unstructured":"Lin, C.-J. et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radical Biol. Med. 52, 377\u2013391 (2012).","journal-title":"Free Radical Biol. Med."},{"key":"4_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055665","volume":"8","author":"AV Knizhnik","year":"2013","unstructured":"Knizhnik, A. V. et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS ONE. 8, e55665 (2013).","journal-title":"PLoS ONE."},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010611-134717","volume":"53","author":"NP Shanware","year":"2013","unstructured":"Shanware, N. P., Bray, K. & Abraham, R. T. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu. Rev. Pharmacol. Toxicol. 53, 89\u2013106 (2013).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/labinvest.3700488","volume":"86","author":"BT Tan","year":"2006","unstructured":"Tan, B. T., Park, C. Y., Ailles, L. E. & Weissman, I. L. The cancer stem cell hypothesis: a work in progress. Lab. Invest. 86, 1203\u20131207 (2006).","journal-title":"Lab. Invest."},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4252\/wjsc.v6.i2.230","volume":"6","author":"NS Bayin","year":"2014","unstructured":"Bayin, N. S., Modrek, A. S. & Placantonakis, D. G. Glioblastoma stem cells: molecular characteristics and therapeutic implications. World J. Stem Cell. 6, 230\u2013238 (2014).","journal-title":"World J. Stem Cell."},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese, A., Bjerkvig, R., Berens, M. E. & Westphal, M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624\u20131636 (2003).","journal-title":"J. Clin. Oncol."},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 20, 810\u2013817 (2011).","journal-title":"Cancer Cell."},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ccr.2011.11.018","volume":"20","author":"CI Ene","year":"2011","unstructured":"Ene, C. I. & Fine, H. A. Many tumors in one: a daunting therapeutic prospect. Cancer Cell. 20, 695\u2013697 (2011).","journal-title":"Cancer Cell."},{"key":"4_CR37","first-page":"153","volume":"88","author":"A Giese","year":"2003","unstructured":"Giese, A. Glioma invasion--pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir. Suppl. 88, 153\u2013162 (2003).","journal-title":"Acta Neurochir. Suppl."},{"key":"4_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/imammb\/dqq011","volume":"29","author":"H Hatzikirou","year":"2012","unstructured":"Hatzikirou, H., Basanta, D., Simon, M., Schaller, K. & Deutsch, A. 'Go or grow': the key to the emergence of invasion in tumour progression? Math Med. Biol. 29, 49\u201365 (2012).","journal-title":"Math Med. Biol."},{"key":"4_CR39","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.057513","volume":"42","author":"L Salphati","year":"2014","unstructured":"Salphati, L. et al. Distribution of the phosphatidylinositol 3-kinase inhibitors pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models: assessment by matrix-assisted laser desorption ionization imaging. Drug Metab. Dispos. 42, 1110 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"4_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/18715206113136660340","volume":"14","author":"G Karpel-Massler","year":"2014","unstructured":"Karpel-Massler, G. et al. Artesunate enhances the antiproliferative effect of temozolomide on u87mg and a172 glioblastoma cell lines. Anticancer Agents Med. Chem. 14, 313\u2013318 (2014).","journal-title":"Anticancer Agents Med. Chem."},{"key":"4_CR41","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1541-7786.MCR-13-0435-T","volume":"11","author":"MA Westhoff","year":"2013","unstructured":"Westhoff, M. A. et al. Inhibition of NF-kappaB signaling ablates the invasive phenotype of glioblastoma. Mol. Cancer Res. 11, 1611\u20131623 (2013).","journal-title":"Mol. Cancer Res."}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-017-0004-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-017-0004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-017-0004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T01:03:24Z","timestamp":1719623004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-017-0004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1038\/s41389-017-0004-8","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,29]]},"assertion":[{"value":"17 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"398"}}